SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

L3Harris Technologies, Inc. engages in the provision of defense and commercial technologies across the air, land, sea, space, and cyber domains. It operates through the following segments: Communication Systems, Integrated Mission Systems, Space and Airborne Systems, and Aerojet Rocketdyne. The Communication Systems segment enables warfighters across all domains with solutions critical to mission success even in the most contested environments. The Integrated Mission Systems segment focuses on the differentiated mission capabilities and prime systems integration for the air, land, and sea domains. The Space and Airborne Systems segment provides full mission solutions as a prime and subsystem integrator in the space, airborne, and cyber domains. The Aerojet Rocketdyne segment includes propulsion, power and armament products and systems to U.S. government, including the DoD, National Aeronautics and Space Administration (“NASA”) and major aerospace and defense prime contractors. The company was founded in 1890 and is headquartered in Melbourne, FL.

L3Harris Technologies Inc

L3Harris Technologies is trending following the announcement that the U.S. Department of War will invest $1 billion in its Missile Solutions business, a move that includes plans to spin off the unit into a standalone public company via an IPO in the second half of 2026. While some investors see this as a strategic move to unlock value and scale manufacturing capacity for critical missile systems, others have expressed concerns regarding share price volatility and the potential impact of broader regulatory scrutiny on the defense sector.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include core, cognitive adjacencies, and cognitive networks. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is trending due to bullish sentiment surrounding its role as a key infrastructure provider for AI data centers, with investors highlighting the company's strong growth and its recent addition to the S&P 100. Traders are actively discussing the stock's positive price action and momentum as it approaches all-time highs, though some remain cautious, debating the sustainability of its current valuation and the potential for a pullback.

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

The primary conversation surrounding Subsquid (SQD) centers on its role as decentralized blockchain data infrastructure, with investors closely watching its integration with Rezolve AI and recent enterprise-level activity. While proponents highlight its potential to outperform legacy indexing solutions like The Graph, skeptics have raised concerns regarding price volatility, token supply mechanics, and skepticism toward promotional behavior on social media.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is trading in a volatile range as investors debate the impact of its strategic partnership with Comcast and the company's long-term growth potential following recent earnings. While some traders are focused on technical support levels and potential institutional accumulation ahead of the upcoming Investor Day, others remain skeptical, citing continued selling pressure and fragmented sentiment.

Duos Technologies Group, Inc. designs, develops, deploys, and operates intelligent technology solutions supporting rail, logistics, intermodal and government customers that streamlines operations, improves safety and reduces costs. It offers imaging, safety and security, software, and services. The firm also provides cutting edge solutions that automate the mechanical and security inspection of fast moving trains, trucks and automobiles through a broad range of proprietary hardware, software, information technology and artificial intelligence. The company was founded on May 31, 1994 and is headquartered in Jacksonville, FL.

Duos Technologies Group Inc

The community is primarily focused on the company's strategic pivot toward AI infrastructure and modular data centers, particularly following the sale of its APR Energy stake and new contracted revenue agreements. Traders are debating the company's growth potential versus concerns over historical dilution and the need for significant capital to fund future infrastructure builds.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is trending following reports of its $10.9 billion acquisition of Apogee Therapeutics, a deal aimed at strengthening its immunology and respiratory pipeline. The acquisition, which involves a cash payment for Apogee shares, has sparked investor discussion regarding the premium paid and the potential long-term value of integrating Apogee's clinical-stage assets.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead Sciences is trending as traders discuss its ongoing pipeline expansion, particularly in oncology and HIV, alongside speculation about potential future acquisitions and reactions to recent earnings. Investors are balancing optimism over the company's long-term commercial strategy with frustration over the stock's relatively steady performance compared to broader market gains.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgen is trending due to a sharp sympathy sell-off triggered by a failed Phase 3 trial of a competitor's cholesterol drug, despite market commentary noting the company's distinct mechanism and robust underlying fundamentals. While some investors are concerned about potential read-through risks to its own pipeline, many traders view the price decline as an overreaction and a buying opportunity.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in Japan, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending as traders debate the potential impact of GameStop's ongoing pursuit of a takeover or strategic partnership, with many discussing the uncertainty surrounding the deal and the recent increase in GameStop's stake in the company. Community sentiment remains polarized, characterized by a mix of speculation regarding the deal's feasibility and concerns over eBay's management and future direction.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The community discussion is fragmented, characterized by a mix of political commentary regarding the upcoming election, concerns over the impact of geopolitical tensions on oil and fuel prices, and technical speculation about market direction amid rising bond yields.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Fortress Biotech, Inc. (NASDAQ: FBIO)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Fortress Biotech, Inc. (NASDAQ: FBIO) SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation...

Fortress Biotech (NASDAQ:FBIO) Issues Quarterly Earnings Results, Misses Estimates By $0.32 EPS

Fortress Biotech (NASDAQ:FBIO - Get Free Report) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the...

Fortress Biotech (NASDAQ:FBIO) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen cut shares of Fortress Biotech from a "buy" rating to a "hold" rating in a report on Saturday...

Fortress Biotech (FBIO) Projected to Post Quarterly Earnings on Monday

Fortress Biotech (NASDAQ:FBIO) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-fortress-biotech-inc-stock...

Fortress Biotech (NASDAQ:FBIO) Cut to "Hold" at Zacks Research

Zacks Research downgraded Fortress Biotech from a "strong-buy" rating to a "hold" rating in a research note on Monday...

Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving Average   - What's Next?

Fortress Biotech (NASDAQ:FBIO) Share Price Crosses Above Two Hundred Day Moving Average - What's Next...

Fortress Biotech (NASDAQ:FBIO) Stock Passes Above Two Hundred Day Moving Average - Here's Why

Fortress Biotech (NASDAQ:FBIO) Stock Passes Above 200 Day Moving Average - Should You Sell...

FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy 

Equity

Fortress said that its majority-owned unit Cyprium Therapeutics has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sentynl Therapeutics. 


Fortress Biotech's (FBIO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated a "buy" rating and issued a $17.00 price objective on shares of Fortress Biotech in a research report on Monday...

Fortress Biotech reported Q1 2026 consolidated net income of $108.4 million, or $2.82 per diluted share, driven by a $205 million priority review voucher sale, compared to a prior year loss.

Fortress Biotech faces risks from failed clinical trial primary endpoints, significant derivative liability charges, and the inherent uncertainty regarding the realization of future milestone and royalty-based revenue streams for Fortress.

Fortress Biotech achieved significant liquidity through the $205 million priority review voucher sale, expanded commercial payer access for Emrosi, and improved the company balance sheet through material debt reduction.

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Fortress Biotech Inc

Bearish Sentiment

President Trump has promised to issue a $5,000 "dividend" check to every adult American citizen if the Republican Party wins control of both the House and the Senate in the upcoming midterm elections, though the proposal would require congressional approval and follows his earlier $2,000 tariff-dividend plan, which stalled after the Supreme Court struck down much of his tariff authority. Do you think the $5,000 dividend check actually happens? Vote and explain your reasoning in the comments.

Trump has pledged a $5,000 &quot;dividend&quot; check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Stocktwits

Trump has pledged a $5,000 "dividend" check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Current Price	$2.52
Prev Close	$2.57
Open	$2.59
Dividend Yield	0.00%
50-Day Moving Average	$3.00
Beta	0.90
Avg. Volume	708,548.58
PE Ratio	0.95

52-Week High	$4.53
52-Week Low	$2.18
Market Capitalization	$85.71M
EPS (Annual)	-$0.0674
Price to Book	0.51
Revenue Per Employee	$811,051.28

Feed

News

Sentiment

Earnings

Fundamentals

Info

FBIO Fundamentals